Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Saturday.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Stock Performance

NASDAQ ORMP opened at $2.44 on Friday. Oramed Pharmaceuticals has a 1 year low of $2.00 and a 1 year high of $3.67. The business’s fifty day moving average is $2.38 and its two-hundred day moving average is $2.41. The stock has a market capitalization of $98.36 million, a P/E ratio of 22.18 and a beta of 1.67.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Several hedge funds have recently made changes to their positions in ORMP. Murchinson Ltd. lifted its stake in Oramed Pharmaceuticals by 23.2% in the 2nd quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock worth $4,369,000 after acquiring an additional 320,495 shares in the last quarter. BML Capital Management LLC increased its holdings in shares of Oramed Pharmaceuticals by 62.1% in the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock valued at $5,334,000 after purchasing an additional 837,153 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Oramed Pharmaceuticals in the third quarter worth approximately $272,000. Dimensional Fund Advisors LP boosted its holdings in shares of Oramed Pharmaceuticals by 52.1% during the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 10,774 shares during the period. Finally, XTX Topco Ltd purchased a new position in Oramed Pharmaceuticals during the second quarter valued at approximately $40,000. Hedge funds and other institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.